Free Trial

UNITY Biotechnology (UBX) Competitors

UNITY Biotechnology logo
$0.18 -0.12 (-40.43%)
Closing price 07/8/2025
Extended Trading
$0.18 0.00 (0.00%)
As of 07/8/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

UBX vs. IMCC, ALVR, IBIO, PHIO, BTAI, AIMD, CYCN, NKGN, PHXM, and LIXT

Should you be buying UNITY Biotechnology stock or one of its competitors? The main competitors of UNITY Biotechnology include IM Cannabis (IMCC), AlloVir (ALVR), iBio (IBIO), Phio Pharmaceuticals (PHIO), BioXcel Therapeutics (BTAI), Ainos (AIMD), Cyclerion Therapeutics (CYCN), NKGen Biotech (NKGN), PHAXIAM Therapeutics (PHXM), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.

UNITY Biotechnology vs. Its Competitors

UNITY Biotechnology (NASDAQ:UBX) and IM Cannabis (NASDAQ:IMCC) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

IM Cannabis has higher revenue and earnings than UNITY Biotechnology. IM Cannabis is trading at a lower price-to-earnings ratio than UNITY Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UNITY BiotechnologyN/AN/A-$25.99M-$1.62-0.11
IM Cannabis$39.44M0.29-$7.72M-$0.64-4.39

UNITY Biotechnology has a net margin of 0.00% compared to IM Cannabis' net margin of -9.10%. IM Cannabis' return on equity of -122.96% beat UNITY Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
UNITY BiotechnologyN/A -246.82% -58.81%
IM Cannabis -9.10%-122.96%-11.69%

29.5% of UNITY Biotechnology shares are held by institutional investors. Comparatively, 7.7% of IM Cannabis shares are held by institutional investors. 5.8% of UNITY Biotechnology shares are held by insiders. Comparatively, 5.9% of IM Cannabis shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

UNITY Biotechnology has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500. Comparatively, IM Cannabis has a beta of 2.19, meaning that its share price is 119% more volatile than the S&P 500.

In the previous week, IM Cannabis had 1 more articles in the media than UNITY Biotechnology. MarketBeat recorded 1 mentions for IM Cannabis and 0 mentions for UNITY Biotechnology. IM Cannabis' average media sentiment score of 1.89 beat UNITY Biotechnology's score of 0.00 indicating that IM Cannabis is being referred to more favorably in the news media.

Company Overall Sentiment
UNITY Biotechnology Neutral
IM Cannabis Very Positive

UNITY Biotechnology currently has a consensus target price of $3.75, indicating a potential upside of 1,994.97%. Given UNITY Biotechnology's stronger consensus rating and higher probable upside, equities research analysts clearly believe UNITY Biotechnology is more favorable than IM Cannabis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
UNITY Biotechnology
0 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.50
IM Cannabis
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

IM Cannabis beats UNITY Biotechnology on 9 of the 15 factors compared between the two stocks.

Get UNITY Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding UBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

UBX vs. The Competition

MetricUNITY BiotechnologyMED IndustryMedical SectorNASDAQ Exchange
Market Cap$3.08M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-0.1121.0428.0720.05
Price / SalesN/A284.46448.5799.42
Price / CashN/A42.7636.2258.56
Price / Book0.468.378.665.87
Net Income-$25.99M-$55.19M$3.25B$258.55M
7 Day PerformanceN/A5.89%4.20%2.23%
1 Month Performance-77.30%17.63%10.82%12.76%
1 Year Performance-87.57%5.09%34.70%19.36%

UNITY Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
UBX
UNITY Biotechnology
4.1328 of 5 stars
$0.18
-40.4%
$3.75
+1,995.0%
-87.7%$3.08MN/A-0.1160Gap Down
High Trading Volume
IMCC
IM Cannabis
0.2356 of 5 stars
$3.04
-11.1%
N/A+29.3%$12.28M$39.44M-4.75340Positive News
Gap Down
ALVR
AlloVir
N/A$2.39
-1.2%
N/A-83.9%$12.05MN/A-0.12110High Trading Volume
IBIO
iBio
1.2553 of 5 stars
$0.73
-0.6%
$4.30
+491.7%
-65.8%$12.00M$375K0.00100
PHIO
Phio Pharmaceuticals
2.8961 of 5 stars
$2.39
-2.4%
$14.00
+485.8%
-30.3%$11.47MN/A-0.3710News Coverage
Positive News
Gap Up
BTAI
BioXcel Therapeutics
3.964 of 5 stars
$1.89
-1.0%
$42.60
+2,154.0%
-90.8%$11.45M$2.27M-0.1490Gap Up
AIMD
Ainos
1.5558 of 5 stars
$2.64
-4.7%
N/A-24.0%$11.06M$20K-0.4140High Trading Volume
CYCN
Cyclerion Therapeutics
2.5328 of 5 stars
$3.37
-4.8%
N/A-8.5%$10.82M$2M-2.9130Positive News
NKGN
NKGen Biotech
0.5901 of 5 stars
$0.24
flat
N/A-83.8%$10.79MN/A-0.05N/AGap Down
PHXM
PHAXIAM Therapeutics
N/A$3.10
flat
N/AN/A$10.58MN/A0.0049
LIXT
Lixte Biotechnology
N/A$3.92
-3.4%
N/A+79.7%$10.51MN/A-2.704Gap Down

Related Companies and Tools


This page (NASDAQ:UBX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners